The market capitalization for Revvity, Inc. (RVTY) is $10.91 Billion, making it a Large Cap company. Market cap is calculated by multiplying the current stock price by the total number of shares outstanding.
Market Capitalization
$10.91B
$10.91 Billion
Calculation
- Stock Price
- $97.82
- Shares Outstanding
- 111.56M
- Market Cap
- $10.91B
Market Cap = Price × Shares Outstanding
Size Classification
Large Cap
$10B - $1T
Companies with market capitalization between $10 billion and $1 trillion.
Market Cap Size Scale
Micro Cap
<$250M
Small Cap
$250M-$2B
Mid Cap
$2B-$10B
Large Cap
$10B-$1T
Mega Cap
>$1T
Related Valuation Metrics
Key Statistics
| Market Cap | $10.91 Billion |
| Stock Price | $97.82 |
| Shares Outstanding | 111.56M |
| Size Category | Large Cap |
| P/E Ratio | 46.58 |
| P/B Ratio | 1.52 |
About Revvity, Inc.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Prahlad R. Singh